Latest Industry Insights
Designing in Sustainability in Science
With a reliance on single-use plastics, significant waste and high energy usage, the carbon footprint of the biopharma industry is large. If we are to accelerate the path to net zero, it is therefore critical to ensure sustainability in science.
2022: The Year We Implement COVID-19 Lessons Into Practice
As we seek a better tomorrow, here are three predictions from global life science and diagnostics company, PerkinElmer, that will lead to better health outcomes.
Transformative Models for Research and Drug Discovery
Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.
Raising the Bar in Proteomics
How do we continue to push the boundaries in analytical capabilities, increase confidence in results and apply MS to a wider range of research questions? Technology Networks posed these questions to Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, in a recent interview.
Addressing the Challenges of AAV Production
Technology Networks spoke to Emily Jackson-Holmes to learn more about the benefits of AAV vectors and reasons for the growing interest in their use.
Reinventing Neuroscience Drug Discovery
Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.
NanoDrop 20 Years On
In this interview, Patrick Brown tells us more about the evolution of NanoDrop over the past 20 years, highlights some of the most important improvements during this time and explores what the future may hold for the technology.
Innovations in Single-Cell Proteomics Drive Advances in Disease Research
Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.
Innovating Reversible Cell Therapies With RNA
In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.
Agilent Science Futures – The Impact of Academia–Industry Relationships on the Next Generation of Scientists
There is an inherent link between academia and industry that rarely gets the acknowledgement it deserves. Hear from a roundtable of PhD students on the impact that the collaborative relationship between academia and industry has on their work and the role that technology plays in the “Science Futures” initiative.